Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 2

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Other neoplasm 1

Conditions

Keratosis, Actinic 4Skin Diseases 1Precancerous Conditions 1Keratosis 1Carcinoma, Basal Cell 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Has results × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT02144077 2022-11-03

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
281 enrolled 16 charts
Dermatologic

Carcinoma, Basal Cell

NCT04319159 2021-11-11

Study to Evaluate the Safety of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Biofrontera Bioscience GmbH

Phase 1 Completed
48 enrolled 27 charts
Dermatologic

Keratosis, Actinic

NCT02799069 2017-04-28

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
571 enrolled 46 charts
Dermatologic

Keratosis, Actinic

NCT02799082 2017-04-06

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Biofrontera Bioscience GmbH

Phase 3 Completed
122 enrolled 24 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon ⚔